Definitive Healthcare Corp. DH
1.25 USD +0.06 (+4.62%)
Nov 11, 2026, 1:27 PM EST
1.20 Day range 1.27
0.61 52-week range 3.00
- YTD
- -56.62%
- 1 year
- -56.62%
News
globenewswire.com Definitive Healthcare Reports Financial Results for Third Quarter 2026 FRAMINGHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare market data and analytics,…
globenewswire.com Definitive Healthcare announces executive appointments to bolster AI-powered initiatives across the company Healthcare Data and Analytics Organization Hires Head of AI and Promotes New Chief Product Officer Healthcare Data and Analytics Organization Hires Head of AI and Promotes New Chief Product Officer
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares…
benzinga.com Definitive Healthcare Appoints Clay Ritchey CEO, Effective Sept. 8, Succeeding Kevin Coop Definitive Healthcare Corp. ("Definitive Healthcare") (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that its Board of Directors has appointed Clay Ritchey…
benzinga.com Morgan Stanley Maintains Equal-Weight on Definitive Healthcare, Lowers Price Target to $1.5 Morgan Stanley analyst Craig Hettenbach maintains Definitive Healthcare (NASDAQ:DH) with a Equal-Weight and lowers the price target from $2.5 to $1.5.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press…
benzinga.com Definitive Healthcare Raises FY2026 Adj EPS Guidance from $0.16-$0.19 to $0.18-$0.20 vs $0.18 Est; Narrows FY2026 Sales Guidance from $220.000M-$226.000M to $220.000M-$222.000M vs $223.449M Est Definitive Healthcare (NASDAQ:DH) raises FY2026 Adj EPS guidance from $0.16-$0.19 to $0.18-$0.20 vs $0.18 analyst estimate. Narrows FY2026 sales outlook from $220.000 million-$226.000 million to…- benzinga.com Definitive Healthcare Sees Q3 Adj EPS $0.04-$0.05 vs $0.04 Est; Sees Sales $54.000M-$55.000M vs $55.542M Est Definitive Healthcare (NASDAQ:DH) is looking for Q3 Adj EPS of $0.04-$0.05 vs $0.04 analyst estimate. sees sales of $54.000 million-$55.000 million vs $55.542 million analyst estimate.
benzinga.com Definitive Healthcare Q2 Adj. EPS $0.05 Beats $0.04 Estimate, Sales $55.195M Miss $55.476M Estimate Definitive Healthcare (NASDAQ:DH) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.04 by 25 percent. This is a 28.57 percent decrease over earnings of…- benzinga.com B of A Securities Downgrades Definitive Healthcare to Underperform, Lowers Price Target to $0.7 B of A Securities analyst Allen Lutz downgrades Definitive Healthcare (NASDAQ:DH) from Buy to Underperform and lowers the price target from $3.5 to $0.7.
- benzinga.com Barclays Maintains Underweight on Definitive Healthcare, Lowers Price Target to $1 Barclays analyst Saket Kalia maintains Definitive Healthcare (NASDAQ:DH) with a Underweight and lowers the price target from $2.75 to $1.
benzinga.com Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1 Health care sector has oversold stocks, RSI momentum indicator can help traders predict short term performance. Latest list of oversold players with RSI below 30: GOSS (26.3), BWAY (19.1), DH (20.2).
benzinga.com Canaccord Genuity Maintains Hold on Definitive Healthcare, Lowers Price Target to $3 Canaccord Genuity analyst David Hynes maintains Definitive Healthcare (NASDAQ:DH) with a Hold and lowers the price target from $4 to $3.
benzinga.com Stephens & Co. Maintains Equal-Weight on Definitive Healthcare, Lowers Price Target to $2 Stephens & Co. analyst Jeff Garro maintains Definitive Healthcare (NASDAQ:DH) with a Equal-Weight and lowers the price target from $3 to $2.
benzinga.com Definitive Healthcare Q4 Earnings Report: What Investors Need to Know - benzinga.com Definitive Healthcare Sees FY2026 Adj EPS $0.14-$0.17 vs $0.26 Est; Sees Sales $220.000M-$226.000M vs $234.138M Est Definitive Healthcare (NASDAQ:DH) is looking for FY2026 Adj EPS of $0.14-$0.17 vs $0.26 analyst estimate. sees sales of $220.000 million-$226.000 million vs $234.138 million analyst estimate.
- benzinga.com Definitive Healthcare Sees Q1 Adj EPS $0.03 vs $0.06 Est; Sees Sales $54.000M-$56.000M vs $57.228M Est Definitive Healthcare (NASDAQ:DH) is looking for Q1 Adj EPS of $0.03 vs $0.06 analyst estimate. sees sales of $54.000 million-$56.000 million vs $57.228 million analyst estimate.
benzinga.com Definitive Healthcare Q4 Adj. EPS $0.06, Inline, Sales $61.534M Beat $59.569M Estimate Definitive Healthcare (NASDAQ:DH) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is a 25 percent decrease over earnings of $0.08 per share from the same…
benzinga.com Earnings Scheduled For February 26, 2026 - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Barclays Maintains Underweight on Definitive Healthcare, Lowers Price Target to $2.75 Barclays analyst Saket Kalia maintains Definitive Healthcare (NASDAQ:DH) with a Underweight and lowers the price target from $3 to $2.75.- benzinga.com Canaccord Genuity Maintains Hold on Definitive Healthcare, Lowers Price Target to $4 Canaccord Genuity analyst David Hynes maintains Definitive Healthcare (NASDAQ:DH) with a Hold and lowers the price target from $5 to $4.
- benzinga.com Definitive Healthcare Raises FY2025 Adj EPS Guidance from $0.22-$0.23 to $0.23-$0.24 vs $0.23 Est; Raises FY2025 Sales Guidance from $237.000M-$240.000M to $239.000M-$240.000M vs $238.424M Est Definitive Healthcare (NASDAQ:DH) raises FY2025 Adj EPS guidance from $0.22-$0.23 to $0.23-$0.24 vs $0.23 analyst estimate. Raises FY2025 sales outlook from $237.000 million-$240.000 million to…
- benzinga.com Definitive Healthcare Sees Q4 Adj EPS $0.05-$0.06 vs $0.06 Est; Sees Sales $59.000M-$60.000M vs $59.148M Est Definitive Healthcare (NASDAQ:DH) is looking for Q4 Adj EPS of $0.05-$0.06 vs $0.06 analyst estimate. sees sales of $59.000 million-$60.000 million vs $59.148 million analyst estimate.
- benzinga.com Definitive Healthcare Q3 Adj. EPS $0.07 Beats $0.06 Estimate, Sales $60.046M Beat $59.488M Estimate Definitive Healthcare (NASDAQ:DH) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.06 by 27.27 percent. This is a 30 percent decrease over earnings of…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Stifel Maintains Buy on Definitive Healthcare, Raises Price Target to $6 Stifel analyst David Grossman maintains Definitive Healthcare (NASDAQ:DH) with a Buy and raises the price target from $5 to $6.
- benzinga.com Definitive Healthcare Raises FY2025 Adj EPS Guidance from $0.20-$0.23 to $0.22-$0.23 vs $0.21 Est; Raises FY2025 Sales Guidance from $234.000M-$240.000M to $237.000M-$240.000M vs $237.041M Est Definitive Healthcare (NASDAQ:DH) raises FY2025 Adj EPS guidance from $0.20-$0.23 to $0.22-$0.23 vs $0.21 analyst estimate. Raises FY2025 sales outlook from $234.000 million-$240.000 million to…
- benzinga.com Definitive Healthcare Sees Q3 Adj EPS $0.05-$0.06 vs $0.06 Est; Sees Sales $59.000M-$60.000M vs $59.215M Est Definitive Healthcare (NASDAQ:DH) is looking for Q3 Adj EPS of $0.05-$0.06 vs $0.06 analyst estimate. sees sales of $59.000 million-$60.000 million vs $59.215 million analyst estimate.
- benzinga.com Definitive Healthcare Q2 Adj. EPS $0.07 Beats $0.05 Estimate, Sales $60.750M Beat $59.200M Estimate Definitive Healthcare (NASDAQ:DH) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.05 by 40 percent. This is a 22.22 percent decrease over earnings of…
- benzinga.com Earnings Scheduled For August 7, 2025
benzinga.com SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com Goldman Sachs Maintains Neutral on Definitive Healthcare, Raises Price Target to $3.4 Goldman Sachs analyst Kash Rangan maintains Definitive Healthcare (NASDAQ:DH) with a Neutral and raises the price target from $3 to $3.4.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Crude Oil Gains Over 1%; EchoStar Posts Q1 Loss 
benzinga.com Insulet Posts Upbeat Earnings, Joins Trade Desk, TransMedics Group, Tesla And Other Big Stocks Moving Higher On Friday 
benzinga.com US Stocks Higher; Lyft Posts Upbeat Earnings - benzinga.com Definitive Healthcare Raises FY25 Outlook: Adj EPS From $0.19-$0.22 to $0.20-$0.23 Vs $0.21 Est; Sales From $230.00M-$240.00M To $234.00M-$240.00M Vs $234.28M Est Full Year 2025: Revenue is expected to be in the range of $234.0 – $240.0 million, raising the bottom end of our prior range by $4.0 million.Adjusted Operating Income is expected to be in the range…
- benzinga.com Definitive Healthcare Sees Q2 Adj EPS $0.04-$0.05 vs $0.05 Est; Sees Sales $58.500M-$60.000M vs $58.29M Est Second Quarter 2025: Revenue is expected to be in the range of $58.5 – $60.0 million. Adjusted Operating Income is expected to be in the range of $12.0 – $13.0 million. Adjusted EBITDA is expected to
benzinga.com Definitive Healthcare Q1 Adj. EPS $0.05 Beats $0.02 Estimate, Sales $59.19M Beat $56.18M Estimate Definitive Healthcare (NASDAQ:DH) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 37.5 percent decrease over earnings of…- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com What 4 Analyst Ratings Have To Say About Definitive Healthcare
- benzinga.com Goldman Sachs Maintains Neutral on Definitive Healthcare, Lowers Price Target to $3 Goldman Sachs analyst Kash Rangan maintains Definitive Healthcare (NASDAQ:DH) with a Neutral and lowers the price target from $4.5 to $3.
- benzinga.com Barclays Maintains Underweight on Definitive Healthcare, Lowers Price Target to $3 Barclays analyst Saket Kalia maintains Definitive Healthcare (NASDAQ:DH) with a Underweight and lowers the price target from $4 to $3.
- benzinga.com Definitive Healthcare Sees Q1 Adj EPS $0.02 vs $0.07 Est; Sees Sales $55.500M-$57.000M vs $59.94M Est Definitive Healthcare (NASDAQ:DH) is looking for Q1 Adj EPS of $0.02 vs $0.07 analyst estimate. sees sales of $55.500 million-$57.000 million vs $59.94 million analyst estimate.
- benzinga.com Definitive Healthcare Sees FY2025 Adj EPS $0.19-$0.22 vs $0.30 Est; Sees Sales $230.000M-$240.000M vs $241.07M Est Definitive Healthcare (NASDAQ:DH) is looking for FY2025 Adj EPS of $0.19-$0.22 vs $0.30 analyst estimate. sees sales of $230.000 million-$240.000 million vs $241.07 million analyst estimate.
- benzinga.com Definitive Healthcare Q4 Adj EPS $0.08 Beats $0.07 Estimate, Sales $62.29M Beat $60.59M Estimate Definitive Healthcare (NASDAQ:DH) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.07 by 14.29 percent. This is a 14.29 percent increase over earnings of…
- benzinga.com Earnings Scheduled For February 27, 2025
benzinga.com Barclays Downgrades Definitive Healthcare to Underweight, Maintains Price Target to $4 Barclays analyst Saket Kalia downgrades Definitive Healthcare (NASDAQ:DH) from Equal-Weight to Underweight and maintains the price target from $4 to $4.